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A B S T R A C T
Purpose
Residual lesions after chemotherapy are frequent in metastatic seminoma. Watchful waiting is
recommended for lesions , 3 cm as well as for ﬂuorodeoxyglucose (FDG) positron emission to-
mography (PET)–negative lesions $ 3 cm. Information on the optimal management of PET-positive
residual lesions $ 3 cm is lacking.
Patients and Methods
We retrospectively identiﬁed 90 patients with metastatic seminoma with PET-positive residual
lesions after chemotherapy. Patients with elevated a-fetoprotein or nonseminomatous histology
were excluded. We analyzed the post-PET management and its impact on relapse and survival and
calculated the positive predictive value (PPV) for PET.
Results
Median follow-up timewas 29months (interquartile range [IQR], 10 to 62months). Median diameter
of the largest residual mass was 4.9 cm (range, 1.1 to 14 cm), with masses located in the retro-
peritoneum (77%), pelvis (16%), mediastinum (17%), and/or lung (3%). Median time from the last
day of chemotherapy to PET was 6.9 weeks (IQR, 4.4 to 9.9 weeks). Post-PET management in-
cluded repeated imaging in 51 patients (57%), resection in 26 patients (29%), biopsy in nine patients
(10%) and radiotherapy in four patients (4%). Histology of the resected specimenwas necrosis in 21
patients (81%) and vital seminoma in ﬁve patients (19%). No biopsy revealed vital seminoma.
Relapse or progression occurred in 15 patients (17%) after a median of 3.7 months (IQR, 2.5 to
4.9 months) and was found in 11 (22%) of 51 patients on repeated imaging, in two (8%) of 26
patients after resection, and in two (22%) of nine patients after biopsy. All but one patient who
experienced relapse were successfully treated with salvage therapy. The PPV for FDG-PET was
23%.
Conclusion
FDG-PET has a low PPV for vital tumor in residual lesions after chemotherapy in patients with
metastatic seminoma. This cautions against clinical decisions based on PET positivity alone.
J Clin Oncol 36:3381-3387. © 2018 by American Society of Clinical Oncology
INTRODUCTION
More than 50% of all germ cell tumors are
seminomas, and the majority of patients present
with localized stage I disease at diagnosis. How-
ever, 20% to 30% of patients with seminoma will
develop metastatic disease1,2 and be successfully
treated with three to four cycles of cisplatin-based
combination chemotherapy.3,4 Residual masses
after chemotherapy are frequent and can be found
in up to 80% of men with advanced-stage
disease.5-7 There is an ongoing controversy re-
garding the optimal postchemotherapy manage-
ment of residual masses . 3 cm in diameter. In
contrast to nonseminomatous germ cell tumors
(nonseminomas), postchemotherapy residual
masses in seminomas almost exclusively contain
necrosis, especially if they are smaller than 3 cm.
Positron emission tomography (PET) scans are
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not recommended for these patients. In patients with residual
masses of $ 3 cm, viable cancer is occasionally found7-9 and may
be identiﬁed by [18F]ﬂuorodeoxy-D-glucose (FDG) PET scanning.
The ﬁrst prospective study investigating the use of PET in this
situation demonstrated a negative predictive value of up to 96%
and a positive predictive value (PPV) of 100%, but subsequent
studies showed that the PPV was only 42%.10,11
Currently, there is no undisputed strategy regarding how to
manage patients with seminoma with PET-positive lesions after
chemotherapy. Therefore, we decided to perform a retrospective
data collection to analyze treatment patterns and outcomes of such
patients.
PATIENTS AND METHODS
Centers collaborating within the Global Germ Cell Cancer Group were
contacted to share data of patients with metastatic seminoma and PET-
positive residual lesions after chemotherapy. Detailed information was
collected anonymously using structured questionnaires, and the planned
data analysis was predeﬁned in a priori written protocol (Data Supple-
ment). Approval of the local ethical committees was obtained before data
collection.
The following items were included: patient characteristics at the time
of starting chemotherapy for metastatic disease; chemotherapy regimen as
well as any additional treatment modalities and the best response to it; time
from last day of chemotherapy to ﬁrst PET scan; detailed PET results as
determined by the local investigator, including standardized uptake value
(SUV) and visual interpretation of equivocal versus deﬁnite positivity;
post-PETmanagement decisions (repeated imaging v resection v biopsy v
radiotherapy); outcome according to the post-PETmanagement decisions
(relapse, histology of resected specimen, or biopsy); and treatment of
relapse and outcome. Relapse was deﬁned as a signiﬁcant increase in
human chorionic gonadotropin (hCG) tumor marker or unequivocal
progression in size of residual lesions or appearance of new lesions. Data
were anonymized locally, transferred, and entered into a joint database
hosted by the Swiss Working Group for Clinical Cancer Research in Bern,
Switzerland.
Patients
The following inclusion criteria were applied: male sex, age 18 years
or older, histologically conﬁrmed pure seminoma, serum a-fetoprotein
, 23 the upper limit of normal at any time; curative-intent chemotherapy
for stage IIB, IIC, or III disease; and residual masses with increased FDG
uptake on PET imaging (according to local investigator) after completion
of chemotherapy.
Patients were excluded if they had nonseminomatous histology or any
other histology apart from seminoma, progressive disease at the time of
ﬁrst PET assessment (increasing hCG or unequivocal progression on
imaging), or other malignant diseases. Patients with responses (partial
response with $ 30% size reduction and hCG negative) or with stable
disease (tumor reduction, 30%, no growth$ 20%, and hCG negative) as
best response after chemotherapy were eligible. Patients with a response
but persistently elevated lactate dehydrogenase were classiﬁed as having
marker-positive partial remissions. Disease stage was reported according to
the International Union Against Cancer classiﬁcation.12 For allocation into
risk categories, the prognostic classiﬁcation of the International Germ Cell
Cancer Consensus Group was used.13
Statistical Analysis
The primary objectives were the management and outcomes (relapse
or histologic ﬁnding of vital seminoma) of patients with a positive PET
scan and the association between outcome and potential prognostic
factors. Secondary objectives were the time from the end of chemotherapy
to the ﬁrst PET scan, the histologies of resection specimens and biopsies,
the treatment and outcomes of patients with relapses, and the calculation
of the PPV of PET.
Follow-up was calculated from the day of the ﬁrst PET to the date of
last contact. Positive PET scans were rated as true positive if either viable
tumor was detected histologically or relapse was diagnosed clinically
during follow-up as deﬁned by signiﬁcantly increasing hCG tumor marker
level or unequivocal progression on imaging; all other positive PET scans
were rated as false positive. Continuous data were summarized using
medians and ranges, categorical data were summarized using frequency
counts and percentages, and time-to-event end points were determined
using the Kaplan-Meier method using median and interquartile range
(IQR). Fisher’s exact test was used to check univariable associations be-
tween variables.
RESULTS
Data from 95 patients with metastatic seminoma and PET-positive
postchemotherapy residual masses detected between March 2003
and September 2016 in 18 different centers or groups from nine
different countries were identiﬁed. Five patients were excluded as
a result of ineligibility, including PET negativity in three patients
and clinically progressive disease at date of ﬁrst PET in two pa-
tients. Therefore, 90 patients with a median follow-up time of
29 months (IQR, 10 to 62 months) were considered eligible
according to protocol and included in the analysis (Fig 1).
Patient Characteristics
Detailed patient characteristics are listed in Table 1. The
median size of the largest PET-positive residual mass was 4.9 cm
(range, 1.1 to 14 cm). Only eight patients (9%) had a residual mass
of , 3 cm. The clinical setting before PETwas ﬁrst-line treatment
in 87 (97%) of 90 patients, including 80 patients with primary
metastatic disease, three patients with relapses after adjuvant
carboplatin, two patients with relapses on active surveillance, and
one patient each with disease progression after adjuvant radio-
therapy or after radiotherapy for stage IIB disease. In three patients
(3%), the clinical setting was salvage treatment after prior che-
motherapy of metastatic disease (one patient each with stage IIB,
IIC, and III disease). Chemotherapy consisted of standard bleo-
mycin, etoposide, and cisplatin (BEP) for three courses in 44
patients (49%); more intensive treatment with BEP for four
courses in 21 patients (23%); BEP for three courses plus one course
of etoposide and cisplatin in ﬁve patients (6%); standard etoposide
and cisplatin for four courses in eight patients (9%); and other
miscellaneous platinum-based combination regimens in 12 pa-
tients (13%).
Primary Management and Outcome
The management of PET-positive patients is shown in
Figure 1. The majority of patients (51 of 90 patients; 57%) were
observed with repeated imaging (including PET, computed to-
mography [CT], or ultrasound), and 11 (22%) of these 51 patients
experienced a relapse. In 26 (29%) of 90 patients, the management
consisted of surgical resection; two (8%) of these 26 patients
experienced a relapse. Nine (10%) of 90 patients had a biopsy, and
two (22%) of these nine patients experienced a relapse.
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Radiotherapy was performed in four (4%) of 90 patients, in whom
no relapses occurred.
Repeated Imaging
Among the 51 patients with repeated imaging, overall 39 pa-
tients (76%) had a subsequent PET. The median time to next PET
scan was 2.9 months. In six (15%) of 39 patients, the PET scan
became negative, and no relapses occurred in those six patients.
Overall, 33 (85%) of 39 patients had a positive PETscan on repeated
imaging. Resections were performed in six (18%) of these 33 pa-
tients, among whom two patients had seminoma in the resected
specimens and no further relapses were observed. The remaining 27
patients (82%) were observed with repeated imaging, and seven of
these patients (26%) experienced relapse. Therefore, even in the case
of repeated positive PET scans, no relapse or vital seminoma was
Table 1. Patient Characteristics
Characteristic All Patients (N = 90)
Patients Who Underwent
Observation (n = 51)
Patients Who Underwent
Resection (n = 26)
Median age, years (range) 41 (19-69) 40 (19-69) 43 (25-53)
Primary tumor, No. (%)
Gonadal 67 (75) 36 (71) 20 (77)
Retroperitoneal 10 (11) 8 (16) 5 (19)
Mediastinal 12 (13) 7 (14) 1 (4)
IGCCCG risk group, No. (%)
Good 80 (91) 46 (94) 23 (88)
Intermediate 8 (9) 3 (6) 3 (12)
Elevated LDH at diagnosis, No. (%) 64 (71) 37 (73) 21 (81)
Elevated hCG at diagnosis, No. (%) 54 (60) 33 (65) 14 (54)
Median size of largest residual mass, cm (range) 4.9 (1.1-14) 4.6 (1.1-13.1) 5.0 (2.3-14)
Site of residual mass, No. (%)
Retroperitoneum 69 (77) 36 (71) 24 (92)
Pelvis 14 (16) 6 (12) 7 (27)
Mediastinum 15 (17) 11 (22) 1 (4)
Lung 3 (3) 2 (4) 0
Median time from last day of chemotherapy to
ﬁrst PET scan, weeks (IQR)
6.9 (4.4-9.9) 7.3 (5.0-10.6) 6.0 (3.9-8.4)
Abbreviations: hCG, human chorionic gonadotropin; IGCCCG, International GermCell Cancer Collaborative Group; IQR, interquartile range; LDH, lactate dehydrogenase;
PET, positron emission tomography.
Patients
(N = 95)
(n = 1)
Patients
(n = 90)
Repeated imaging
(n = 51; 57%)
Primary resection
(n = 26; 29%)
Primary biopsy
(n = 9; 10%) 
Primary radiotherapy
(n = 4; 4%)
Relapse
(n = 11; 22%)
Seminoma in
specimen
(n = 2; 33%)
Relapse
(n = 0; 0%)
Relapse*
(n = 2; 8%)
Seminoma in
specimen*
(n = 5; 19%)
Relapse 
(n = 2; 22%)
Seminoma in
specimen
(n = 0; 0%)
Repeated PET:
Secondary
resection
(n = 6)
PET negative                          (n = 3)
PD on first PET                       (n = 1)
PD with increasing hCG 
  at first PET                            (n = 1)
Fig 1. Overview of patients. (*) One patient with seminoma in the resected specimen had a later relapse and is included in both boxes. hCG, human chorionic
gonadotropin; PD, progressive disease; PET, positron emission tomography.
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found in 24 (73%) of 33 patients. Another 12 (24%) of 51 patients
had CTscans, of whom four patients (33%) experienced progression.
Surgical Resection
In total, 32 (36%) of 90 patients underwent resection of a PET-
positive residual lesion; 26 (81%) of 32 patients underwent im-
mediate resection after the ﬁrst positive PET, and six (19%) of 32
patients underwent resection after a subsequent PET that demon-
strated continued positivity. The majority of resections (29 of 32
resections; 91%) were performed in patients with masses in the
retroperitoneum and/or pelvis, and only three resections were for
masses in themediastinum. Vital seminomawas found in ﬁve (19%)
of 26 patients with immediate resection of PET-positive lesions and
in two (33%) of six patients with a second positive PET scan. In 25
(78%) of 32 patients who underwent resection, only necrosis was
found. One of the resected patients received two cycles of adjuvant
cisplatin and etoposide chemotherapy, and two patients were treated
with postoperative adjuvant radiotherapy to the resection site. Viable
seminoma was found in the retroperitoneum or pelvis but not in the
mediastinum. Two patients suffered a relapse at the resection site
after immediate surgery of PET-positive lesions despite reported
complete resections (one after resection of necrosis and one after
resection of vital seminoma). Local investigators reported serious
postoperative complications in six (19%) of 32 patients, including
chylous ascites, pulmonary embolism, bilateral jugular deep vein
thrombosis, retroperitoneal hematoma, adhesion with intestinal
pseudo-obstruction, and retrograde ejaculation.
Biopsy
Biopsies for histologic assessment were obtained using core
needle biopsies or open techniques (eg, mediastinoscopy). None of
the nine biopsies from PET-positive residual masses revealed semi-
noma on histologic work-up. The following histologic results were
found: sarcoidosis (n = 2), necrosis (n = 2), ﬁbrosis (n = 1), abscess
(n = 1), reactive lymphoid tissue (n = 1), desmoid tumor (n = 1), and
schwannoma (n = 1). Two relapses occurred at biopsy sites. One
relapse was identiﬁed after 67 days in a patient in whom the initial
postchemotherapy biopsy had shown necrosis. The other relapse
occurred in a PET-negative retroperitoneal residualmass 28 days after
a biopsy had shown schwannoma at a PET-positive presacral lesion.
Radiotherapy
Only four patients had immediate radiotherapy of a residual
PET-positive lesion without further diagnostic procedures. One
patient had received high-dose chemotherapy and autologous stem-
cell transplantation for relapsed seminoma and demonstrated a PET-
positive residual lesion in the right iliac/inguinal area. The other
three patients had retroperitoneal disease after BEP, including two
patients with marker-negative PET-positive partial remissions and
one patient with marker-negative PET-positive stable disease. None
of the irradiated patients experienced a relapse.
Risk Factors for Relapse or Presence of Vital Seminoma
and Outcome of Relapse
The risk of relapse or presence of vital seminoma in the
resection specimen according to different clinical variables was
investigated in univariable analyses (Data Supplement), but no
factor achieved statistical signiﬁcance. Visual interpretation of
FDG activity and response to prior chemotherapy revealed a trend
(P = .06). To further elucidate the impact of visual PET inter-
pretation, we analyzed the relapse rate for each primary man-
agement according to visual PET interpretation demonstrating no
major imbalance between the groups (Data Supplement). Actual
SUV results were available for 73 (81%) of 90 patients; patients
with relapse had higher SUV values than patients without relapse
(median SUV, 4.2 v 3.6, respectively; P = .02), but no cutoff value
with an improved PPV could be deﬁned.
Table 2 provides a summary of all 15 patients who expe-
rienced relapse. Relapses occurred within a maximum of 129 days
after initial PET or resection or biopsy. Two of ﬁve patients with
marker-positive partial remissions and four of eight patients with
stable disease experienced a relapse or had vital seminoma in the
resected specimen. Of note, relapses occurred at the site of re-
sidual masses in all patients; in three patients, additional met-
astatic sites were found. One patient died during salvage
treatment from progressive disease, but all other patients were
successfully treated with salvage therapy using conventional-dose
chemotherapy in two patients and high-dose chemotherapy
followed by autologous stem-cell transplantation in 12 (80%) of
15 patients.
At the time of last follow-up, 56 (62%) of 90 patients were
reported to be in complete remission, 32 (36%) of 90 patients had
residual but inactive disease, one patient was lost to follow-up, and
one patient had died of progressive disease.
PPV of PET
The PPVof PETwas calculated for all patients as well as for
the following subgroups: equivocal or deﬁnite PET positivity on
visual interpretation; PET performed within 6 weeks after last
day of chemotherapy or later; SUV cutoff value of 4; and size of
residual lesion cutoff of 3 cm. The results are listed in Table 3.
The PPV for the entire patient population is low at 23%. None of
the subgroups revealed meaningful improvement of PPV, with
values of 29% for patients with deﬁnite PET positivity, 19% if
PET was performed later than 6 weeks after the end of che-
motherapy, 32% in case of SUV of $ 4, and 22% if the residual
lesion was $ 3 cm.
DISCUSSION
This report summarizes the results of the analysis of the largest
cohort of patients with metastatic seminoma with PET-positive
residual masses after chemotherapy. In contrast to previous smaller
series with only a few PET-positive patients included (ranging from
eight to 33 patients), our data could not conﬁrm a favorable PPVof
PET in this setting.10,11,14,15 We calculated a PPV of only 23% for
a group of patients that consisted mainly of the target population
with residual masses . 3 cm. Subgroup analyses using more
stringent additional criteria, including unequivocal PET positivity,
elevated SUVof$ 4, PETscanning later than 6 weeks after the end
of chemotherapy, and residual mass size of $ 3 cm, did not
substantially improve the PPV; these analyses resulted in PPVs of
only 29%, 32%, 19%, and 22%, respectively.
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The high rate of false-positive PET scans can be explained by
the histologic ﬁndings. Among 41 patients with further evaluation
of positive scans by either biopsy or resection, vital seminoma was
only found in seven (17%) of 41 patients. Necrosis was the most
frequent ﬁnding, but other histologies such as sarcoidosis, ﬁbrosis,
inﬂammation, and benign tumors were also associated with false-
positive FDG activity.
Relapses were detected in 17% of patients, all at the site of
residual disease and all within 4 months after the end of che-
motherapy. Importantly, all patients with relapse except one were
treated successfully with salvage treatment using conventional-
dose or high-dose chemotherapy. This suggests that intensiﬁed or
prolonged follow-up of PET-positive patients with seminoma or
repeated PET scanning is unnecessary because patients with re-
sidual vital seminoma will eventually be identiﬁed by regular
follow-up schedules.
Patients undergoing surgical resections of PET-positive re-
sidual masses had a low relapse rate of only 8% as compared with
22% in case of follow-up using repeated imaging. This corresponds
to an absolute risk reduction of 14% and a relative risk reduction of
64%. On the basis of these ﬁgures, the number needed to resect to
prevent one relapse would be eight. Resections of large post-
chemotherapy masses in seminoma are challenging, however, and
often associated with severe complications.16 Moreover, the fact
that necrosis was the only histologic ﬁnding in approximately 80%
of resected patients conﬁrms that PET is an inappropriate tool to
reliably predict viable seminoma after chemotherapy or to identify
patients who might beneﬁt from additional postchemotherapy
treatments. In the near future, novel serum biomarkers such as
microRNA might help to identify patients with vital residual
tumor.17
None of four PET-positive patients experienced relapse after
additional radiotherapy. However, because no histologic in-
formation is available in those patients, the impact of additional
radiotherapy cannot be assessed. The use of additional radio-
therapy is nevertheless discouraged in patients with PET-positive
residual lesions because the likelihood of overtreatment is
high18,19 and late toxicities after treatment with both che-
motherapy and radiotherapy are known to be markedly
increased.20,21
An unexpected ﬁnding of our analysis is the fact that patients
who presented initially with large seminomamasses may have been
exposed to overtreatment; although only 9% of patients were
classiﬁed as intermediate risk according to the International Germ
Cell Cancer Consensus Group classiﬁcation, a total of 29% of
patients received four cycles of a cisplatin-based three-drug com-
bination. Hence, one of ﬁve patients may have received a fourth
cycle possibly based on the impression of large tumor masses and/
or elevated lactate dehydrogenase, which is not recommended by
current guidelines.
This report has all the limitations inherent in a retrospec-
tive study and is only hypothesis generating. The data are
susceptible to selection bias and may not be representative for
all patients with seminoma; for example, among eight patients
with residual lesions , 3 cm, the rate of viable seminoma or
relapse was unexpectedly high. Moreover, because we did not
centrally reassess the original PET scans, we had to rely on
assessments by local investigators, which might have intro-
duced interobserver bias. The facts that technical improve-
ments in PET scanning and reporting had occurred during the
study period and that current state-of-the-art SUV measure-
ments are not available for all patients in this series are other
drawbacks.
Although our report represents the largest analysis in this
patient population, the total number of patients is still small.
Without prospective randomized studies, no deﬁnite recom-
mendations as to the optimal management of patients with
seminoma with residual masses after chemotherapy can be
made. Because the probability of vital seminoma is reported
to be low in most series, there is consensus among experts that
PET should not be used in residual lesions measuring , 3 cm
in the largest diameter.3 Such patients can be observed according
to published guidelines,3,4 with imaging (magnetic resonance
imaging or CT) after 6 and 12 months and annually thereafter
up to 5 years. For residual lesions $ 3 cm, we recommend
to perform PET not earlier than 6 weeks after completion
of chemotherapy. In view of the high negative predictive value
of 96%,11 PET-negative patients can be observed according
to the aforementioned schedule. In case of a positive PET scan
after chemotherapy, we propose to closely monitor patients
with repeated imaging (CT or magnetic resonance imaging),
tumor marker measurements, and clinical assessment after 2
and 4 months and every 4 months thereafter in the ﬁrst year,
every 6 months in the second year, and then annually up to
5 years. On the basis of the results of the current analysis, bi-
opsies of residual lesions are discouraged. Surgical resection of
PET-positive residual lesions may be considered on an individual
basis on the basis of size, location, resectability, and patient
preference. For patients with unequivocal progression, salvage
chemotherapy is recommended and will result in a high rate of
cure.
Despite its limitations, the results of this retrospective study
challenge the clinical relevance of positive PET scans in patients
with metastatic seminoma and residual masses after chemotherapy
and caution against additional treatments on the basis of PET
positivity alone. Given their rarity and complexity, such patients
should be referred to centers with expertise in managing germ cell
tumors.
Table 3. PPV for All Patients and for Predeﬁned Subgroups
Patient Group
No. of
Patients
Viable Tumor
Detection
Method (No.)
Result, No. (%)
PPV (%)Histology FU
True
Positive
False
Positive
All patients 90 7 14 21 (23) 69 (77) 23
PET equivocal 28 2 1 3 (11) 25 (89) 11
PET deﬁnite 62 5 13 18 (29) 44 (71) 29
PET # 6 weeks 37 4 7 11 (29) 26 (71) 29
PET . 6 weeks 53 3 7 10 (19) 43 (81) 19
PET SUV $ 4 34 3 8 11 (32) 23 (68) 32
PET SUV , 4 39 4 4 8 (21) 31 (79) 21
Lesion , 3 cm 8 1 2 3 (38) 5 (62) 38
Lesion $ 3 cm 82 6 12 18 (22) 64 (78) 22
Abbreviations: FU, follow-up; PET, positron emission tomography; PPV, positive
predictive value; SUV, standard uptake value.
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